Treatment is recommended for all patients with chronic HCV infection, except those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy.
A 12-week SOF/VEL regimen is the therapy of choice regardless of the stage of fibrosis both in treatment-naive patients and for retherapy. Ribavirin is added to therapy in cases of decompensated cirrhosis.
The optimum therapeutic option is a 12-week SOF/VEL regimen, combined with RBV in patients with cirrhosis.
Overall the combination of Sofosbuvir (400mg) + Velpatasvir (100mg), is a pangenotypic, and is recommended for all genotype 1,2,3,4,5 or 6.